Immune cells supercharged to fight ovarian cancer

This early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-boosting drugs (Sylatron and Actimmune), and then infused them back into the abdomen. The goal was to find the safest dose and see if this approach could slow tumor growth. The study was stopped early, but it involved 18 women and focused on safety and dosing.